December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

98.77 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
25 26 Next >
News headline image
Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025
From Incyte
Via Business Wire
News headline image
Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet
From Incyte
Via Business Wire
News headline image
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
News headline image
Where Incyte Stands With Analysts ↗
 
Via Benzinga
News headline image
Earnings Scheduled For April 29, 2025 ↗
 
Via Benzinga
News headline image
Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025
From Incyte
Via Business Wire
News headline image
INCYTE CORP (NASDAQ:INCY) – A Potential Undervalued Opportunity in Biotech ↗
INCYTE CORP (NASDAQ:INCY) presents a compelling value case with strong profitability, low debt, and an attractive valuation. The biotech firm's fundamentals suggest potential upside for long-term... 
Via Chartmill
News headline image
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
News headline image
What's going on in today's session: S&P500 movers ↗
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Tuesday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
News headline image
3 Mid-Cap Stocks with Questionable Fundamentals
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract... 
Via StockStory
News headline image
Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States
From Incyte
Via Business Wire
News headline image
INCY Q1 Earnings Call: New Product Launches and Pipeline Progress Drive Outperformance
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 19.5% year on year to $1.05 billion. Its non-GAAP profit... 
Via StockStory
Topics World Trade
News headline image
These S&P500 stocks that are showing activity before the opening bell on Thursday. ↗
Curious about the S&P500 stocks that are showing activity before the opening bell on Thursday? 
Via Chartmill
News headline image
INCYTE CORP (NASDAQ:INCY), an undervalued stock with good fundamentals. ↗
INCYTE CORP may be an undervalued stock option. NASDAQ:INCY retains a strong financial foundation and an attractive price tag. 
Via Chartmill
News headline image
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
News headline image
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
News headline image
INCYTE CORP (NASDAQ:INCY) – A Look at Its Dividend Potential ↗
INCYTE CORP (NASDAQ:INCY) – A Look at Its Dividend Potential 
Via Chartmill
News headline image
9 Analysts Have This To Say About Incyte ↗
 
Via Benzinga
News headline image
Discover the top S&P500 movers in Tuesday's after-hours session. ↗
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top S&P500 gainers and losers driving the post-market movements. 
Via Chartmill
News headline image
Tuesday's pre-market session: top gainers and losers in the S&P500 index ↗
Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
Stocks Surge And Bond Yields Fall For 6th Day, Oil Prices Drop To $60: What's Driving Markets Tuesday? ↗
Wall Street modestly up as investors await economic data and corporate earnings. Bond market continues rally, gold and oil prices fall.Wall Street rises modestly, bond market continues rally, gold and... 
Via Benzinga
Topics Bonds
News headline image
3 Value Stocks Facing Headwinds
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few... 
Via StockStory
News headline image
Incyte (NASDAQ:INCY) Delivers Strong Q1 Numbers
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 19.5% year on year to $1.05 billion. Its non-GAAP profit... 
Via StockStory
News headline image
Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
News headline image
Incyte (INCY) Q1 Earnings Report Preview: What To Look For
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting results tomorrow morning. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence Government World Trade
News headline image
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025
From Incyte
Via Business Wire
News headline image
Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
From Incyte
Via Business Wire
News headline image
INCYTE CORP (NASDAQ:INCY) is probably undervalued for the fundamentals it is displaying. ↗
Take a closer look at INCYTE CORP , a remarkable value stock. NASDAQ:INCY excels in fundamentals and maintains a very reasonable valuation. 
Via Chartmill
News headline image
Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Exact Sciences (NASDAQ:EXAS) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
Reflecting On Immuno-Oncology Stocks’ Q4 Earnings: Regeneron (NASDAQ:REGN)
Looking back on immuno-oncology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Regeneron (NASDAQ:REGN) and its peers. 
Via StockStory
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
25 26 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.